Optiscan Initiates Head and Neck Cancer Study in the US

Key points

• Optiscan has initiated a new U.S.-based head and neck cancer imaging study.
• The study will evaluate the performance of Optiscan's InVue and InForm platforms.
• Patient recruitment has begun at Mayo Clinic Rochester.

Full summary

Optiscan Imaging Ltd (ASX: OIL) has initiated a new U.S.-based head and neck cancer imaging study in collaboration with Mayo Clinic. This study aims to evaluate the performance of Optiscan's InVue and InForm platforms in assessing surgical margins in head and neck cancer patients. The study will involve 35 patients and is expected to generate data that will support Optiscan's planned U.S. FDA submissions for both devices later in calendar 2026. The clinical study will explore the use of InVue and InForm within the surgical and pathology workflow, focusing on their ability to provide high-resolution imaging in real-time during and after head and neck cancer surgical resection.